Personalis, Inc. (PSNL) shareholders
Close on Nov 17, 2026Market cap $1.58BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Merck & Co., Inc. Joint filing with Merck Sharp & Dohme LLC (16.50%) | 14,044,943 | 16.50% | 13G (passive) | Dec 19, 2024 |
| Eric Lefkofsky Joint filing with Tempus AI, Inc. (12.50%) | 13,189,067 | 12.60% | 13D (active) amendment | Jul 19, 2026 |
| Ravi Mhatre Joint filing with Peter Y. Nieh (11.71%), Barry Eggers (11.70%) and 5 more | 8,160,734 | 15.71% | 13D (active) amendment | Jun 28, 2024 |
| ARK Investment Management LLC Joint filing with Catherine D. Wood (8.14%) | 7,188,197 | 8.14% | 13G (passive) amendment | Mar 31, 2025 |
| BlackRock, Inc. | 6,169,729 | 5.90% | 13G (passive) | Jun 30, 2026 |
| Ameriprise Financial, Inc. | 6,086,315 | 5.80% | 13G (passive) amendment | Jun 30, 2026 |
| Deep Track Capital, LP Joint filing with Deep Track Biotechnology Master Fund, Ltd. (5.51%), David Kroin (5.51%) | 5,760,627 | 5.51% | 13G (passive) | May 5, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PSNL | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Merck & Co., Inc. | 14,044,943 | 13.15% | $188.20M | – | 35.75% |
| ARK Investment Management LLC | 8,271,339 | 7.74% | $110.84M | +327,227 | 0.72% |
| BlackRock, Inc. | 7,082,491 | 6.63% | $94.91M | +1,692,606 | 0.00% |
| Lightspeed Management Company, L.L.C. | 6,101,850 | 5.71% | $81.76M | −2,058,884 | 3.40% |
| Ameriprise Financial Inc | 6,086,315 | 5.70% | $81.56M | −1,506,492 | 0.02% |
| Deep Track Capital, LP | 4,000,000 | 3.75% | $53.60M | +1,000,000 | 0.78% |
| abrdn plc | 3,747,290 | 3.51% | $50.21M | +258,982 | 0.07% |
| Vanguard Capital Management LLC | 3,010,150 | 2.82% | $40.34M | +141,687 | 0.00% |
| Casdin Capital, LLC | 2,550,000 | 2.39% | $34.17M | +950,000 | 1.71% |
| Kennedy Capital Management LLC | 2,364,282 | 2.21% | $31.68M | +180,710 | 0.56% |
| Geode Capital Management, LLC | 1,822,445 | 1.71% | $24.43M | +524,790 | 0.00% |
| Bank Of America Corp /De/ | 1,820,541 | 1.70% | $24.40M | +1,709,235 | 0.00% |
| AIGH Capital Management LLC | 1,715,000 | 1.61% | $22.98M | −1,185,000 | 1.45% |
| Blue Water Life Science Advisors, LP | 1,676,300 | 1.57% | $22.46M | – | 14.15% |
| Dimensional Fund Advisors LP | 1,496,983 | 1.40% | $20.06M | +430,735 | 0.00% |
| State Street Corp | 1,487,077 | 1.39% | $19.93M | +352,907 | 0.00% |
| Morgan Stanley | 1,270,946 | 1.19% | $17.03M | +1,033,631 | 0.00% |
| Goldman Sachs Group Inc | 931,031 | 0.87% | $12.48M | +193,899 | 0.00% |
| Hrt Financial LP | 930,816 | 0.87% | $12.47M | +721,925 | 0.00% |
| Nuveen, LLC | 753,004 | 0.71% | $10.09M | +409,484 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 159 | 85M | 79.6% | 43 / 68 | 34 / 22 | 15M | 15M |
| Q1 2026 | 140 | 85M | 79.2% | 36 / 47 | 36 / 20 | 15M | 10M |
| Q4 2025 | 126 | 83M | 77.7% | 31 / 36 | 39 / 14 | 23M | 4M |
| Q3 2025 | 109 | 65M | 60.6% | 20 / 31 | 35 / 16 | 7M | 3M |
| Q2 2025 | 105 | 61M | 56.7% | 33 / 35 | 24 / 31 | 11M | 5M |
| Q1 2025 | 104 | 55M | 51.3% | 19 / 43 | 26 / 21 | 5M | 2M |
| Q4 2024 | 107 | 52M | 48.3% | 31 / 24 | 36 / 6 | 26M | 3M |
| Q3 2024 | 83 | 29M | 27.5% | 24 / 17 | 28 / 8 | 13M | 3M |
| Q2 2024 | 69 | 22M | 20.6% | 7 / 11 | 30 / 9 | 1M | 2M |
| Q1 2024 | 71 | 23M | 21.1% | 8 / 27 | 23 / 6 | 2M | 2M |
| Q4 2023 | 69 | 22M | 20.7% | 15 / 20 | 18 / 7 | 3M | 6M |
| Q3 2023 | 62 | 25M | 23.1% | 6 / 11 | 24 / 10 | 0M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
142 funds held PSNL in Q2 2026, 66% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of PSNL | Value | % of fund | As of |
|---|---|---|---|---|---|
| ARK Genomic Revolution ETF | 6,733,812 | 6.31% | $85.25M | 5.47% | Jul 31, 2026 |
| Vanguard Total Stock Market Index Fund | 2,142,395 | 2.01% | $28.71M | 0.00% | Jun 30, 2026 |
| Columbia Small Cap Growth Fund | 1,874,189 | 1.75% | $21.37M | 0.58% | May 31, 2026 |
| iShares Russell 2000 ETF | 1,728,539 | 1.62% | $23.16M | 0.03% | Jun 30, 2026 |
| Columbia Acorn Fund | 1,277,628 | 1.20% | $17.12M | 0.62% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 796,069 | 0.75% | $10.67M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 743,346 | 0.70% | $9.41M | 0.03% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 617,592 | 0.58% | $8.28M | 0.06% | Jun 30, 2026 |
| Nuveen Quant Small Cap Equity Fund | 570,030 | 0.53% | $7.22M | 0.18% | Jul 31, 2026 |
| Strategic Advisers U.S. Total Stock Fund | 567,752 | 0.53% | $6.47M | 0.01% | May 31, 2026 |
| iShares Biotechnology ETF | 437,150 | 0.41% | $5.86M | 0.06% | Jun 30, 2026 |
| BlackRock Advantage Small Cap Core Fund | 359,792 | 0.34% | $4.10M | 0.08% | May 29, 2026 |
| Dimensional U.S. Small Cap ETF | 340,010 | 0.32% | $4.30M | 0.03% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 278,616 | 0.26% | $3.18M | 0.01% | May 31, 2026 |
| U.S. Small Cap Portfolio | 266,249 | 0.25% | $3.37M | 0.02% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Christopher M. Hall | Chief Executive Officer, Director | 199,415 | 0.19% | Nov 4, 2026 |
| Richard Chen | President and CMO | 169,882 | 0.16% | Sep 22, 2026 |
| Stephen Michael Moore | SVP and Chief Legal Officer | 90,257 | 0.08% | Sep 22, 2026 |
| Aaron Tachibana | CFO AND COO | 195,902 | 0.18% | Sep 22, 2026 |
| Karin Eastham | Director | 19,756 | 0.02% | Jun 11, 2026 |
| Lonnie Shoff | Director | 37,190 | 0.03% | May 14, 2026 |
| A. Blaine Bowman | Director | 19,756 | 0.02% | May 14, 2026 |
| Olivia Kyusuk Bloom | Director | 27,265 | 0.03% | May 14, 2026 |
| Woodrow A. Myers Jr | Director | 32,366 | 0.03% | May 14, 2026 |
| Kenneth J. Widder | Director | 6,250 | 0.01% | May 14, 2026 |
| Tempus AI, Inc. | 10% owner | 13,039,067 | 12.21% | Feb 13, 2026 |
| Sharp & Dohme Llc Merck | 10% owner | 14,044,943 | 13.15% | Dec 23, 2024 |
| Merck & Co., Inc. | 10% owner | – | – | Dec 23, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Christopher M. Hall Chief Executive Officer, Director | Nov 3, 2026 | Sale | −29,112 | $15.87 | $462.01K | 199,415 |
| Christopher M. Hall Chief Executive Officer, Director | Sep 18, 2026 | Sale | −7,459 | $16.22 | $120.98K | 228,527 |
| Aaron Tachibana CFO AND COO | Sep 18, 2026 | Sale | −2,931 | $16.22 | $47.54K | 195,902 |
| Richard Chen President and CMO | Sep 18, 2026 | Sale | −3,998 | $16.22 | $64.85K | 169,882 |
| Stephen Michael Moore SVP and Chief Legal Officer | Sep 18, 2026 | Sale | −2,068 | $16.22 | $33.54K | 90,257 |
| Richard Chen President and CMO | Jul 15, 2026 | Option exercise | +100,000 | $2.44 | $244.00K | 273,880 |
| Richard Chen President and CMO | Jul 15, 2026 | Sale(10b5-1 plan) | −100,000 | $15.15 | $1.52M | 173,880 |
| Christopher M. Hall Chief Executive Officer, Director | Jul 9, 2026 | Sale(10b5-1 plan) | −100,000 | $15.08 | $1.51M | 235,986 |
| Christopher M. Hall Chief Executive Officer, Director | Jul 9, 2026 | Option exercise | +100,000 | $1.61 | $161.00K | 335,986 |
| Aaron Tachibana CFO AND COO | Jun 29, 2026 | Option exercise | +4,982 | $5.32 | $26.50K | 203,815 |
| Aaron Tachibana CFO AND COO | Jun 29, 2026 | Sale(10b5-1 plan) | −4,982 | $14.00 | $69.75K | 198,833 |
| Christopher M. Hall Chief Executive Officer, Director | Jun 26, 2026 | Sale(10b5-1 plan) | −100,000 | $13.15 | $1.32M | 235,986 |
| Christopher M. Hall Chief Executive Officer, Director | Jun 26, 2026 | Option exercise | +100,000 | $1.61 | $161.00K | 335,986 |
| Aaron Tachibana CFO AND COO | Jun 26, 2026 | Sale(10b5-1 plan) | −51,251 | $13.18 | $675.49K | 198,833 |
| Aaron Tachibana CFO AND COO | Jun 26, 2026 | Option exercise | +28,832 | $9.16 | $264.10K | 227,665 |
| Aaron Tachibana CFO AND COO | Jun 26, 2026 | Option exercise | +22,419 | $5.32 | $119.27K | 250,084 |
| Aaron Tachibana CFO AND COO | Jun 4, 2026 | Option exercise | +40,000 | $9.16 | $366.40K | 238,833 |
| Aaron Tachibana CFO AND COO | Jun 4, 2026 | Sale(10b5-1 plan) | −40,000 | $12.01 | $480.40K | 198,833 |
| Christopher M. Hall Chief Executive Officer, Director | May 29, 2026 | Option exercise | +80,091 | $1.61 | $128.95K | 316,077 |
| Christopher M. Hall Chief Executive Officer, Director | May 29, 2026 | Sale(10b5-1 plan) | −80,091 | $11.02 | $882.60K | 235,986 |
| Aaron Tachibana CFO AND COO | May 29, 2026 | Sale(10b5-1 plan) | −38,799 | $11.58 | $449.29K | 198,833 |
| Aaron Tachibana CFO AND COO | May 29, 2026 | Option exercise | +38,799 | $9.16 | $355.40K | 237,632 |
| Christopher M. Hall Chief Executive Officer, Director | May 28, 2026 | Sale(10b5-1 plan) | −19,909 | $11.02 | $219.40K | 235,986 |
| Christopher M. Hall Chief Executive Officer, Director | May 28, 2026 | Option exercise | +19,909 | $1.61 | $32.05K | 255,895 |
| Karin Eastham Director | May 12, 2026 | Award | +6,250 | – | – | 19,756 |
| Olivia Kyusuk Bloom Director | May 12, 2026 | Award | +6,250 | – | – | 27,265 |
| A. Blaine Bowman Director | May 12, 2026 | Award | +6,250 | – | – | 19,756 |
| Kenneth J. Widder Director | May 12, 2026 | Award | +6,250 | – | – | 6,250 |
| Woodrow A. Myers Jr Director | May 12, 2026 | Award | +6,250 | – | – | 32,366 |
| Karin Eastham Director | May 12, 2026 | Award | +6,250 | – | – | 22,366 |
| Lonnie Shoff Director | May 12, 2026 | Award | +6,250 | – | – | 37,190 |
| Aaron Tachibana CFO AND COO | Mar 15, 2026 | Award | +34,375 | – | – | 198,833 |
| Richard Chen President and CMO | Mar 15, 2026 | Award | +46,875 | – | – | 173,880 |
| Christopher M. Hall Chief Executive Officer, Director | Mar 15, 2026 | Award | +87,500 | – | – | 235,986 |
| Stephen Michael Moore SVP and Chief Legal Officer | Mar 15, 2026 | Award | +28,125 | – | – | 92,325 |
| Aaron Tachibana CFO AND COO | Jan 22, 2026 | Option exercise | +1,201 | $9.16 | $11.00K | 165,659 |
| Aaron Tachibana CFO AND COO | Jan 22, 2026 | Sale(10b5-1 plan) | −1,201 | $11.50 | $13.81K | 164,458 |
| Tempus AI, Inc. 10% owner | Dec 22, 2025 | Buy | +28,000 | $8.93 | $250.04K | 13,039,067 |
| Tempus AI, Inc. 10% owner | Dec 19, 2025 | Buy | +29,641 | $8.39 | $248.69K | 13,011,067 |
| Tempus AI, Inc. 10% owner | Dec 18, 2025 | Buy | +31,430 | $7.91 | $248.61K | 12,981,426 |
| Tempus AI, Inc. 10% owner | Dec 17, 2025 | Buy | +31,650 | $7.86 | $248.77K | 12,949,996 |
| Tempus AI, Inc. 10% owner | Nov 25, 2025 | Buy | +9,712 | $10.08 | $97.90K | 12,904,458 |
| Tempus AI, Inc. 10% owner | Nov 25, 2025 | Buy | +13,888 | $11.00 | $152.77K | 12,918,346 |
| Aaron Tachibana CFO AND COO | Nov 25, 2025 | Option exercise | +103,668 | $9.16 | $949.60K | 268,126 |
| Aaron Tachibana CFO AND COO | Nov 25, 2025 | Sale(10b5-1 plan) | −103,668 | $10.78 | $1.12M | 164,458 |
| Tempus AI, Inc. 10% owner | Nov 24, 2025 | Buy | +25,225 | $9.87 | $248.97K | 12,894,746 |
| Tempus AI, Inc. 10% owner | Nov 21, 2025 | Buy | +16,599 | $9.74 | $161.67K | 12,869,521 |
| Tempus AI, Inc. 10% owner | Nov 21, 2025 | Buy | +9,900 | $8.84 | $87.52K | 12,852,922 |
| Tempus AI, Inc. 10% owner | Nov 20, 2025 | Buy | +28,827 | $8.63 | $248.78K | 12,843,022 |
| Tempus AI, Inc. 10% owner | Nov 19, 2025 | Buy | +30,645 | $8.12 | $248.84K | 12,814,195 |
| Tempus AI, Inc. 10% owner | Nov 18, 2025 | Buy | +64,750 | $7.67 | $496.63K | 12,783,550 |
| Christopher M. Hall PRESIDENT AND CEO, Director | Nov 3, 2025 | Sale | −29,612 | $8.99 | $266.21K | 148,486 |
| Aaron Tachibana CFO AND COO | Jul 28, 2025 | Sale | −641 | $6.57 | $4.21K | 164,458 |
| Richard Chen CHIEF MEDICAL OFFICER AND EVP | Jul 28, 2025 | Sale | −452 | $6.57 | $2.97K | 124,505 |
| Aaron Tachibana CFO AND COO | May 16, 2025 | Sale | −1,291 | $4.95 | $6.39K | 165,099 |
| Richard Chen CHIEF MEDICAL OFFICER AND EVP | May 16, 2025 | Sale | −910 | $4.95 | $4.50K | 124,957 |
| Stephen Michael Moore SVP and Chief Legal Officer | May 16, 2025 | Sale | −1,675 | $4.95 | $8.29K | 64,200 |
| Aaron Tachibana CFO AND COO | Jan 28, 2025 | Sale | −708 | $5.79 | $4.10K | 166,390 |
| Richard Chen CHIEF MEDICAL OFFICER AND EVP | Jan 28, 2025 | Sale | −519 | $5.79 | $3.01K | 123,367 |
| Richard Chen CHIEF MEDICAL OFFICER AND EVP | Dec 16, 2024 | Sale | −4,834 | $3.82 | $18.47K | 123,886 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Personalis's stock actually held short. Settlement fails (shares not delivered on time) peaked at 134,956 shares on Sep 8, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Richard Chen Officer | Jul 15, 2026 | 100,000 | $1.50M | Jul 15, 2026 | Exercise of Stock Options |
| Chris Hall Director, Officer | Jul 9, 2026 | 100,000 | $1.41M | Jul 9, 2026 | Exercise of Stock Options |
| Aaron Tachibana Officer | Jun 29, 2026 | 4,982 | $64.87K | Jun 29, 2026 | Exercise of Stock Options |
| Chris Hall Director, Officer | Jun 26, 2026 | 100,000 | $1.26M | Jun 26, 2026 | Exercise of Stock Options |
| Aaron Tachibana Officer | Jun 26, 2026 | 51,251 | $645.25K | Jun 26, 2026 | Exercise of Stock Options |
| Aaron Tachibana Officer | Jun 4, 2026 | 40,000 | $431.20K | Jun 4, 2026 | Exercise of Stock Options |
| Aaron Tachibana Officer | May 29, 2026 | 38,799 | $426.01K | May 29, 2026 | Exercise of Stock Options |
| Christopher M. Hall Director, Officer | May 28, 2026 | 100,000 | $949.00K | May 28, 2026 | Exercise of Stock Options |
| Aaron Tachibana Officer | Jan 22, 2026 | 40,000 | $386.00K | Jan 22, 2026 | Exercise of Stock Options |
| Aaron Tachibana Officer | Nov 25, 2025 | 103,668 | $1.04M | Nov 25, 2025 | Exercise of Stock Options |
Congress trades
3 trades in Personalis reported by 1 member of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Brian Mast FL21 | Sold | May 19, 2020 | $15K | Jun 4, 2020 |
| Brian Mast FL21 | Sold | Apr 22, 2020 | $1K–15K | May 4, 2020 |
| Brian Mast FL21 | Bought | Feb 14, 2020 | $15K | Mar 4, 2020 |
See a number that looks wrong?